Seahorse Bioscience XF Analyzers and stress test kits are the industry standard in cellular bioenergetic measurements. It enables cloud-based sharing of the elements and protocols of metabolic experiments, affording new users and experts the opportunity to collaborate and accelerate their research. The XF e Analyzer sets a universal standard for acquiring and reporting cell metabolism data. The new XF e Analyzer is designed to enable the scientific community to build a knowledgebase that will turn cell metabolism into a target of new therapies for neurodegenerative disease.
"Our decision to launch this landmark product at Neuroscience was strategic in that XF technology has already enabled a new focus on metabolic dysfunction as a therapeutic target in Autism, Alzheimer's, Parkinson's, traumatic brain injury, diabetes induced cognitive dysfunction, migraines, and neuroprotection," stated Jay Teich, Founder and CEO of Seahorse Bioscience. With this information we have now expanded our investigation into potential therapeutic candidates for AD prevention and treatment, and the XF96 Analyzer provides the throughput capacity for preclinical screening." Brinton's lab added, "The XF Analyzer has also enabled us to demonstrate that estrogen, a neuroprotective steroid, differentially potentiates the metabolic function of neurons and glia. Roberta Brinton from the University of Southern California, Los Angeles, CA. With the XF Analyzer we were able to demonstrate that mitochondrial bioenergetics deficits are evident in neurons from AD transgenic mice at the embryonic stage," stated Dr. "Our lab's aim is to identify the role of mitochondrial dysfunction in Alzheimer's Disease (AD) pathogenesis, with the ultimate goal of developing therapeutics that target mitochondrial bioenergetics for AD prevention and treatment.
The XF e Analyzer is able to identify mitochondrial dysfunction and subtle changes in neuronal cell metabolism before the development of observable neurodegeneration. The XF e Analyzer and stress test kits are the Gold Standard platform for metabolic assays in neuroscience. It's titled Analysis of respiratory defects in primary neurons from BACHD transgenic rats. "XF data is shown in our poster #54.17 that Trophos Senior Scientist, Caroline Gouarne, Ph.D., will present at Neuroscience on Saturday, Octoat 1:00 PM. "XF technology plays an important role in our drug development efforts as we explore innovative therapeutics for the under-served needs in neurology," stated Rebecca Pruss, Ph.D., CSO of Trophos. This knowledge is generating new insights into mitochondrial respiration and glycolysis and their impact on new treatments of neurodegenerative diseases. The XF e Analyzer and stress test kits have standardized the measurements of mitochondrial dysfunction and glycolysis, enabling scientists to better understand the connection between physiological traits of cells with genomic and proteomic data. The Seahorse Bioscience XF e Extracellular Flux Analyzer measures the two major energy pathways of the cell - mitochondrial respiration and glycolysis - in a microplate, in real-time. 14, 2012 /PRNewswire/ - Seahorse Bioscience, the world leader in instruments and assay kits for measuring cell metabolism, unveiled XF e - the world's most advanced cell metabolism analyzer - at the Society for Neuroscience's 42nd Annual Meeting, in New Orleans, October 13-17.